ARCHIVES

Drug Marketing; Zeneca sues Eli Lilly, Claiming Misleading Promotion of Evista

This article is from The Cancer Letter archive.

Vol. 25 No. 10 | March 12, 1999

Download PDF Visit The Full Archive

Related Articles

Economic Analyses Of New Therapies Useful In Phase III Studies, Trialists Say

July 24, 2009

Ethics Commission to Meet In L.A.

September 4, 1981

ODAC Recommends TICE BCG Approval For Recurrent Bladder Cancer Prevention

January 10, 1997

Science Fellowships Available; Grants For Former Soviet Scientists

August 16, 1996

NCI Programs: Institute Partners With Two Groups On Psychosocial Issues

May 16, 1997

MGI Pharma’s Irofulven In Phase III Trial Vs. 5-FU For Advanced Pancreatic Cancer.

March 2, 2001